Mandate

Vinge represents ADB BVBA in connection with the acquisition of Safegate

February 26, 2016

Vinge, together with Willkie Farr & Gallagher, represents ADB BVBA, a portfolio company to the French private equity fund PAI Partners, in its acquisition of Safegate from Fairford. Together they will form the new ADB Safegate group.

Safegate is a leading airfield solutions business providing aircraft docking guidance systems, gate management systems, airfield lighting solutions and air traffic control systems to more than 1,300 airports in 130 countries. Safegate is headquartered in Malmö, Sweden, has more than 300 employees worldwide and generated revenue of SEK 1.3 billion in 2015. The ADB Group comprises ADB Airfield Solutions, LUCEBIT and ERNI AGL, three world-leading airfield technology companies specializing in end-to-end, integrated and sustainable solutions for visual guidance. The ADB Group has a worldwide presence and experience spanning 69 years in airfield lighting. More than 2000 airports in 175 countries have chosen ADB as their preferred partner for airside operations.

Vinge’s team primarily consisted of Jonas Bergström, Maria Dahlin, Ulrich Ziche, Samra Baytar, Manne Bergström, Linn Adelwald, Adam Sandberg, Maria Schultzberg, Jasmin Draszka-Ali, Carl Sander, Isabell Nielsen and Lova Unge.

Related

Vinge has advised Verisure in connection with its IPO on Nasdaq Stockholm

Vinge has advised Verisure plc (“Verisure”) in connection with its IPO on Nasdaq Stockholm. Following the publication of the prospectus on 29 September 2025, trading in Verisure’s shares commenced today, 8 October 2025.
October 08, 2025

Vinge has acted for Advania on the acquisition of smartvokat

smartvokat GmbH, a German-based consultancy specialising in digital transformation within the legal, risk, and compliance domains, will become part of Advania’s business unit Transformation & Automation.
October 08, 2025

Vinge has advised Egetis Therapeutics in connection with a directed share issue

Vinge has advised Egetis Therapeutics AB (publ) (“Egetis Therapeutics”), listed on Nasdaq Stockholm, in connection with a directed share issue whereby Egetis Therapeutics raised proceeds of approximately SEK 183 million before transaction costs.
October 06, 2025